Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.58 |
| ▸ | PTGIR | P43119 | 1/20 | 0.52 |
| ▸ | WDR5 | P61964 | 10/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.49 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10054979 | 0.82 | PTGIR (0.69) | PTGIRWDR5SMN1; SMN2NLRP3LMNA | |
| SCHEMBL17974342 | 0.82 | CYP2D6 (0.51) | CYP2D6NFKB1TAAR1PTGIRWDR5 | |
| SCHEMBL3169468 | 0.81 | PTGIR (0.60) | CYP2D6TAAR1PTGIRWDR5SMN1; SMN2 | |
| SCHEMBL8152769 | 0.78 | WDR5 (0.69) | CYP2D6PTGIRWDR5 | |
| SCHEMBL6666027 | 0.77 | WDR5 (0.65) | CYP2D6PTGIRWDR5NISCHLMNA | |
| SCHEMBL6300545 | 0.77 | WDR5 (0.53) | CYP2D6PTGIRWDR5SMN1; SMN2NLRP3 | |
| Iodide SCHEMBL3180056 | 0.77 | WDR5 (0.67) | CYP2D6PTGIRWDR5 | |
| SCHEMBL13063072 | 0.77 | WDR5 (0.55) | PTGIRWDR5NISCH | |
| SCHEMBL17188814 | 0.77 | WDR5 (0.56) | PTGIRWDR5SMN1; SMN2NLRP3LMNA | |
| SCHEMBL4032956 | 0.76 | PTGIR (0.62) | PTGIRWDR5SMN1; SMN2NLRP3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858653-B2 | 2-imidazoles | HOFFMAN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20080146634-A1 | 2-IMIDAZOLES | HOFFMANN-LA ROCHE INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146634-A1 | 2-IMIDAZOLES | ABL1, H1-2, IPO4 | CYP2D6 158/4885NFKB1 3166/4885TAAR1 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.